Login to Your Account



$400M Deal for Protez Gives Novartis Superbug Candidate

By Tiffany Turner


Thursday, June 5, 2008
Protez Pharmaceuticals is being purchased by Novartis AG in a $400 million deal that could shift development of its broad-spectrum antibiotic into high gear. Company shareholders will net $100 million up front and $300 million upon meeting clinical milestones and obtaining regulatory approval. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription